Settles with Pfizer's subsidiary on Restasis patent


I see this as somewhat good news for Allergan and bad news for Mylan, Teva, etc. If their case for overturning the patents was that strong then Innopharma would not have been willing to make a deal.
 
I see this as somewhat good news for Allergan and bad news for Mylan, Teva, etc. If their case for overturning the patents was that strong then Innopharma would not have been willing to make a deal.

Spoke too soon bud
 


Write your reply...